Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 126-131

  Gressner, Olav A ^a   Fang, Meng ^b   Li, Hui ^b   Lu, Lun Gen ^c   Gressner, Axel M ^a   Gao, Chun Fang ^b,d  

^a Wisplinghoff Medical Laboratories   (Germany)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

Author keywords

Biomarker; Connective tissue growth factor; Hepatocellular carcinoma; Liver fibrosis; Transforming growth factor beta

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

ADULT; ALBUMINS; BIOLOGICAL MARKERS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; GENE EXPRESSION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84875765445     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.02.029     Document Type: Article

References (38)

1. Bosetti C., Levi F., Lucchini F., Zatonski W.A., Negri E., La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007, 46:827-829.
2. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
3. Gressner O.A., Rizk M.S., Kovalenko E., Weiskirchen R., Gressner A.M. Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go?. J Gastroenterol Hepatol 2008, 23:1024-1035.
4. Bedossa P., Dargere D., Paradis V. Sample variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1149-1157.
5. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008, 48:835-847.
6. Friedrich-Rust M., Wunder K., Kriener S., et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009, 25:595-604.
7. Gressner A.M., Gao Chun Fang, Gressner O.A. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol 2009, 28:2433-2440.
8. Gressner O.A., Weiskirchen R., Gressner A.M. Biomarkers of hepatic fibrosis, fibrogenesis, and genetic predisposition pending between fiction and reality. J Cell Mol Med 2007, 11:1031-1051.
9. Martinez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-335.
10. Gressner O.A., Beer N., Jodlowski A., Gressner A.M. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis. Clin Chim Acta 2009, 409:90-95.
11. Leask A., Denton C.P., Abraham D.J. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 2004, 122:1-6.
12. Lipson K.E., Wong C., Teng Y., Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogen Tissue Rep 2012, 5(Suppl. 1):S24.
13. Leask A., Abraham D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006, 119:4803-4810.
14. George J., Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007, 14:790-803.
15. Gressner O.A., Lahme B., Demirci I., Gressner A.M., Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007, 47:699-710.
16. Gressner A.M., Yagmur E., Lahme B., Gressner O., Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 2006, 52:1815-1817.
17. Kovalenko E., Tacke F., Gressner O.A., et al. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepatol 2009, 16:612-620.
18. Gressner A.M., Rizk M., Gao C.F. Potential novel biomarkers for monitoring the fibrogenic process in liver. Arab J Gastroenterol 2010, 10:S12-S16.
19. TNM classification of malignant tumors 2002, Wiley, New York. 6th ed. L.H. Sobin, C.L. Wittekind (Eds.).
20. Child C.G., Turcotte J.G. Surgery and portal hypertension. The liver and portal hypertension 1964, 50-64. WB Saunders, Philadelphia. C.G. Child (Ed.).
21. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513-1520.
22. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
23. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 98:125-172.
24. Young A.L., Adair R., Prasad K.R., Toogood G.J., Lodge J.P. Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes. J Am Coll Surg 2012, 214:174-183.
25. Mazzocca A., Fransvea E., Dituri F., Lupo L., Antonaci S., Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor β blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010, 51:523-534.
26. Gressner O.A., Gressner A.M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008, 28:1065-1079.
27. Leivonen S.K., Häkkinen L., Liu D., Kähäri V.M. Smad3 and extracellular signal-regulated kinase1/2 coordinately mediate transforming growth factor-β-induced expression of connective tissue growth factor in human fibroblast. J Invest Dermatol 2005, 124:1162-1169.
28. Gressner O.A., Lahme B., Siluschek M., Rehbein K., Weiskirchen R., Gressner A.M. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes - but without modulating bone morphogenetic protein 7 signaling. Hepatology 2009, 49:2021-2030.
29. Leask A., Holmes A., Black C.M., Abraham D.J. Connective tissue growth factor gene regulation. Requirement for its induction by transforming growth factor-β2 in fibroblasts. J Biol Chem 2003, 278:13008-13015.
30. Gressner O.A., Lahme B., Siluschek M., et al. Activation of TGF-β within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J Cell Mol Med 2008, 12:2717-2730.
31. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat Cell Biol 2002, 4:599-603.
32. Hayashi N., Kakimuma T., Soma Y., et al. Connective tissue growth factor is directly related to liver fibrosis. Hepatogastroenterology 2002, 49:133-135.
33. Li G., Xie Q., Shi Y., et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006, 8:889-900.
34. Hyytiäinen M., Penttinen C., Keski-oja J. Latent TGF-β binding proteins: extracellular matrix association and roles in TGF-β activation. Crit Rev Clin Lab Sci 2004, 41:233-264.
35. Breitkopf K., Lahme B., Tag C.G. Expression and matrix deposition of latent transforming growth factor ß binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001, 33:387-396.
36. Crookston K.P., Webb D.J., Lamarre J., Gonias S.L. Binding of platelet-derived growth factor BB and transforming growth factor-β to alpha 2-macroglobulin in vitro and in vivo: comparison of receptor-recognized and non-recognized alpha 2-macroglobulin conformation. Biochem J 1993, 293:443-450.
37. Grainger D.J., Mosedale D.E., Metcalfe J.C. TGF-β in blood: a complex problem. Cytokine Growth Factor Rev 2000, 11:133-145.
38. Gressner O.A., Weiskirchen R., Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007, 381:107-113.